GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (NAS:EXAS) » Definitions » Cash Flow from Investing

Exact Sciences (Exact Sciences) Cash Flow from Investing : $50 Mil (TTM As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Exact Sciences Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Exact Sciences spent $35 Mil on purchasing property, plant, equipment. It gained $0 Mil from selling property, plant, and equipment. It spent $13 Mil on purchasing business. It gained $0 Mil from selling business. It spent $65 Mil on purchasing investments. It gained $55 Mil from selling investments. It paid $0Mil for net Intangibles purchase and sale. And it paid $9 Mil for other investing activities. In all, Exact Sciences spent $67 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Exact Sciences Cash Flow from Investing Historical Data

The historical data trend for Exact Sciences's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Cash Flow from Investing Chart

Exact Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -124.43 -702.04 -1,082.09 74.07 49.68

Exact Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -58.16 82.94 66.47 -32.97 -66.77

Exact Sciences Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Exact Sciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Exact Sciences's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exact Sciences  (NAS:EXAS) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Exact Sciences's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-35 Mil. It means Exact Sciences spent $35 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Exact Sciences's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0 Mil. It means Exact Sciences gained $0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Exact Sciences's purchase of business for the three months ended in Dec. 2023 was $-13 Mil. It means Exact Sciences spent $13 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Exact Sciences's sale of business for the three months ended in Dec. 2023 was $0 Mil. It means Exact Sciences gained $0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Exact Sciences's purchase of investment for the three months ended in Dec. 2023 was $-65 Mil. It means Exact Sciences spent {stock_data.stock.currency_symbol}}65 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Exact Sciences's sale of investment for the three months ended in Dec. 2023 was $55 Mil. It means Exact Sciences gained $55 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Exact Sciences's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0 Mil. It means Exact Sciences paid $0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Exact Sciences's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0 Mil. It means Exact Sciences paid $0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Exact Sciences's cash from other investing activities for the three months ended in Dec. 2023 was $-9 Mil. It means Exact Sciences paid $9 Mil for other investing activities.


Exact Sciences Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences (Exact Sciences) Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Executives
Brian Baranick officer: Gen. Mgr., Precision Oncology 441 CHARMANY DRIVE, MADISON WI 53719
Sarah Condella officer: SVP, Human Resources 441 CHARMANY DRIVE, MADISON WI 53719
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Everett Cunningham officer: Chief Commercial Officer C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeffrey Thomas Elliott officer: Chief Financial Officer 5505 ENDEAVOR LANE, MADISON WI 53719
James Edward Doyle director 5505 ENDEAVOR LANE, MADISON WI 53719
James Herriott officer: General Counsel 5505 ENDEAVOR LANE, MADISON WI 53719
Katherine S Zanotti director 431 E 9TH STREET, HINSDALE IL 60521
Jacob A Orville officer: General Manager, New Ventures 5505 ENDEAVOR LANE, MADISON WI 53719
Kevin T Conroy director, officer: Vice President 5505 ENDEAVOR LANE, MADISON WI 53719
D Scott Coward officer: SVP and General Counsel 441 CHARMANY DRIVE, MADISON WI 53719
Paul J Clancy director C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Graham Peter Lidgard officer: SVP, Chief Scientific Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Torsten Hoof officer: General Manager, International 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063